| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network CJ Voskens, SM Goldinger, C Loquai, C Robert, KC Kaehler, C Berking, ... PloS one 8 (1), e53745, 2013 | 504 | 2013 |
| Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo A Fischer, S Zundler, R Atreya, T Rath, C Voskens, S Hirschmann, ... Gut 65 (10), 1642-1664, 2016 | 178 | 2016 |
| Fc-dependent expression of CD137 on human NK cells: insights into “agonistic” effects of anti-CD137 monoclonal antibodies W Lin, CJ Voskens, X Zhang, DG Schindler, A Wood, E Burch, Y Wei, ... Blood, The Journal of the American Society of Hematology 112 (3), 699-707, 2008 | 164 | 2008 |
| Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells B Dietel, I Cicha, CJ Voskens, E Verhoeven, S Achenbach, CD Garlichs Atherosclerosis 230 (1), 92-99, 2013 | 131 | 2013 |
| FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck RJ Taylor, SL Chan, A Wood, CJ Voskens, JS Wolf, W Lin, A Chapoval, ... Cancer Immunology, Immunotherapy 58, 997-1006, 2009 | 124 | 2009 |
| Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody … CJ Voskens, R Watanabe, S Rollins, D Campana, K Hasumi, DL Mann Journal of Experimental & Clinical Cancer Research 29, 1-13, 2010 | 116 | 2010 |
| The α4β1 homing pathway is essential for ileal homing of Crohn's disease effector T cells in vivo S Zundler, A Fischer, D Schillinger, MT Binder, R Atreya, T Rath, ... Inflammatory bowel diseases 23 (3), 379-391, 2017 | 112 | 2017 |
| CD137 promotes proliferation and survival of human B cells X Zhang, CJ Voskens, M Sallin, A Maniar, CL Montes, Y Zhang, W Lin, ... The journal of immunology 184 (2), 787-795, 2010 | 111 | 2010 |
| Intestinal mucosal wound healing and barrier integrity in IBD–crosstalk and trafficking of cellular players K Sommer, M Wiendl, TM Müller, K Heidbreder, C Voskens, MF Neurath, ... Frontiers in medicine 8, 643973, 2021 | 106 | 2021 |
| Induction of MAGE‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma CJ Voskens, D Sewell, R Hertzano, J DeSanto, S Rollins, M Lee, R Taylor, ... Head & neck 34 (12), 1734-1746, 2012 | 82 | 2012 |
| Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells C Mark, T Czerwinski, S Roessner, A Mainka, F Hörsch, L Heublein, ... Nature communications 11 (1), 5224, 2020 | 70 | 2020 |
| Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis C Voskens, D Stoica, M Rosenberg, F Vitali, S Zundler, M Ganslmayer, ... Gut 72 (1), 49-53, 2023 | 53 | 2023 |
| Anti–cytotoxic t-cell lymphocyte antigen-4–induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss C Voskens, A Cavallaro, M Erdmann, O Dippel, E Kaempgen, G Schuler, ... Journal of Clinical Oncology 30 (33), e356-e357, 2012 | 46 | 2012 |
| Residual homing of α4β7-expressing β1+ PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab E Becker, M Dedden, C Gall, M Wiendl, AB Ekici, A Schulz-Kuhnt, ... Gut 71 (8), 1551-1566, 2022 | 36 | 2022 |
| Targeting immune cell trafficking–insights from research models and implications for future IBD therapy M Wiendl, E Becker, TM Müller, CJ Voskens, MF Neurath, S Zundler Frontiers in immunology 12, 656452, 2021 | 34 | 2021 |
| Characterization and expansion of autologous GMP-ready regulatory T cells for TREG-based cell therapy in patients with ulcerative colitis CJ Voskens, A Fischer, S Roessner, C Lorenz, S Hirschmann, R Atreya, ... Inflammatory Bowel Diseases 23 (8), 1348-1359, 2017 | 33 | 2017 |
| NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells NC Bosch, RE Voll, CJ Voskens, S Gross, B Seliger, G Schuler, N Schaft, ... Therapeutic advances in medical oncology 11, 1758835919891622, 2019 | 28 | 2019 |
| Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune … M Wiesinger, D Stoica, S Roessner, C Lorenz, A Fischer, R Atreya, ... Frontiers in Immunology 8, 1371, 2017 | 28 | 2017 |
| Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome CJ Voskens, SE Strome, DA Sewell Current molecular medicine 9 (6), 683-693, 2009 | 25 | 2009 |
| Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label … CJ Voskens, D Stoica, S Roessner, F Vitali, S Zundler, M Rosenberg, ... BMJ open 11 (12), e049208, 2021 | 13 | 2021 |
